Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se

Referenser

  1. Dykewicz CA, Centers for Disease C, Prevention, Infectious Diseases Society of A, American Society of B, Marrow T. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2001;33(2):139-44.
  2. Salehi S, Eloranta S, Johansson AL, Bergstrom M, Lambe M. Reporting and incidence trends of hydatidiform mole in Sweden 1973-2004. Acta oncologica. 2011;50(3):367-72.
  3. Flam F, Lundstrom-Lindstedt V, Rutqvist LE. Incidence of gestational trophoblastic disease in Stockholm County, 1975-1988. European journal of epidemiology. 1992;8(2):173-7.
  4. Joneborg U, Marions, L. Current clinical features of complete and partial hydatiform mole in Sweden. J Reprod Med. 2013;58:in press.
  5. Tham B. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. BJOG: An International Journal of Obstetrics and Gynaecology. 2003;110(6):555-9.
  6. Fukunaga M, Ushigome S, Endo Y. Incidence of hydatidiform mole in a Tokyo hospital: a 5-year (1989 to 1993) prospective, morphological, and flow cytometric study. Human pathology. 1995;26(7):758-64.
  7. Jeffers MD, O'Dwyer P, Curran B, Leader M, Gillan JE. Partial hydatidiform mole: a common but underdiagnosed condition. A 3-year retrospective clinicopathological and DNA flow cytometric analysis. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 1993;12(4):315-23.
  8. Vree, M., ten Kate-Booij, M., Lok, C., Massuger, L., van trommel, N., Sweep, F. Risks of vagina metastases in GTN. ISSTD Word Congress XVII, Chicago (2013).
  9. Savage, P. Brain metastases in GTT update on incidence, management and outcome. ISSTD Word Congress XVII, Chicago (2013).
  10. Horowitz NS, Goldstein DP, Berkowitz RS. Management of gestational trophoblastic neoplasia. Seminars in oncology. 2009;36(2):181-9.
  11. Vree, M. Lung metastases in gestational trophoblastic disease. ISSTD Word Congress XVII, Chicago (2013).
  12. Lawler SD, Pickthall VJ, Fisher RA, Povey S, Evans MW, Szulman AE. Genetic studies of complete and partial hydatidiform moles. Lancet. 1979;2(8142):580.
  13. Niemann I, Petersen LK, Hansen ES, Sunde L. Differences in current clinical features of diploid and triploid hydatidiform mole. BJOG : an international journal of obstetrics and gynaecology. 2007;114(10):1273-7.
  14. Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, Kuick R, et al. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nature genetics. 2006;38(3):300-2.
  15. Parry DA, Logan CV, Hayward BE, Shires M, Landolsi H, Diggle C, et al. Mutations causing familial biparental hydatidiform mole implicate c6orf221 as a possible regulator of genomic imprinting in the human oocyte. American journal of human genetics. 2011;89(3):451-8.
  16. Williams D, Hodgetts V, Gupta J. Recurrent hydatidiform moles. European journal of obstetrics, gynecology, and reproductive biology. 2010;150(1):3-7.
  17. Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. BJOG : an international journal of obstetrics and gynaecology. 2002;109(1):99-102.
  18. Petignat P, Vassilakos P, Campana A. Are fertility drugs a risk factor for persistent trophoblastic tumour? Human reproduction. 2002;17(6):1610-5.
  19. Gynaecologists TRCoOa. The Royal College of Obstetricians and Gynaecologists, Green-top Guidelines. London2006. p. 1-18.
  20. Stenman UH, Alfthan H, Hotakainen K. Human chorionic gonadotropin in cancer. Clinical biochemistry. 2004;37(7):549-61.
  21. Sturgeon CM, Berger P, Bidart JM, Birken S, Burns C, Norman RJ, et al. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clinical chemistry. 2009;55(8):1484-91.
  22. Harvey RA, Mitchell HD, Stenman UH, Blankenstein MA, Nustad K, Stieber P, et al. Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors. J Reprod Med. 2010;55(7-8):285-95.
  23. Sturgeon CM, Viljoen A. Analytical error and interference in immunoassay: minimizing risk. Annals of clinical biochemistry. 2011;48(Pt 5):418-32.
  24. Stenman UH. Standardization of assays for human chorionic gonadotropin. Clinical chemistry. 2004;50(5):798-800.
  25. Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, management, and long-term followup of 347 patients. Obstetrics and gynecology. 1975;45(1):1-8.
  26. Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2006;27(1):56-60.
  27. Joneborg U, Marions L. Current clinical features of complete and partial hydatidiform mole in Sweden. J Reprod Med. 2014;59(1-2):51-5.
  28. Soto-Wright V, Bernstein M, Goldstein DP, Berkowitz RS. The changing clinical presentation of complete molar pregnancy. Obstetrics and gynecology. 1995;86(5):775-9.
  29. Mangili G, Garavaglia E, Cavoretto P, Gentile C, Scarfone G, Rabaiotti E. Clinical presentation of hydatidiform mole in northern Italy: has it changed in the last 20 years? American journal of obstetrics and gynecology. 2008;198(3):302 e1-4.
  30. Hou JL, Wan XR, Xiang Y, Qi QW, Yang XY. Changes of clinical features in hydatidiform mole: analysis of 113 cases. J Reprod Med. 2008;53(8):629-33.
  31. Coukos G, Makrigiannakis A, Chung J, Randall TC, Rubin SC, Benjamin I. Complete hydatidiform mole. A disease with a changing profile. J Reprod Med. 1999;44(8):698-704.
  32. Gemer O, Segal S, Kopmar A, Sassoon E. The current clinical presentation of complete molar pregnancy. Archives of gynecology and obstetrics. 2000;264(1):33-4.
  33. Berkowitz RS, Goldstein DP, Bernstein MR. Natural history of partial molar pregnancy. Obstetrics and gynecology. 1985;66(5):677-81.
  34. Czernobilsky B, Barash A, Lancet M. Partial moles: a clinicopathologic study of 25 cases. Obstetrics and gynecology. 1982;59(1):75-7.
  35. Soper JT, Mutch DG, Schink JC, American College of O, Gynecologists. Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecologic oncology. 2004;93(3):575-85.
  36. Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(2):280-6.
  37. Papadopoulos AJ, Foskett M, Seckl MJ, McNeish I, Paradinas FJ, Rees H, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med. 2002;47(6):460-4.
  38. Sebire NJ, Lindsay I. Current issues in the histopathology of gestational trophoblastic tumors. Fetal and pediatric pathology. 2010;29(1):30-44.
  39. Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet. 2009;374(9683):48-55.
  40. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717-29.
  41. Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. The American journal of surgical pathology. 1998;22(11):1393-403.
  42. Hamazaki S, Nakamoto S, Okino T, Tsukayama C, Mori M, Taguchi K, et al. Epithelioid trophoblastic tumor: morphological and immunohistochemical study of three lung lesions. Human pathology. 1999;30(11):1321-7.
  43. Shen DH, Khoo US, Ngan HY, Ng TY, Chau MT, Xue WC, et al. Coexisting epithelioid trophoblastic tumor and choriocarcinoma of the uterus following a chemoresistant hydatidiform mole. Archives of pathology & laboratory medicine. 2003;127(7):e291-3.
  44. Fadare O, Parkash V, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: clinicopathological features with an emphasis on uterine cervical involvement. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2006;19(1):75-82.
  45. Palmer JE, Macdonald M, Wells M, Hancock BW, Tidy JA. Epithelioid trophoblastic tumor: a review of the literature. J Reprod Med. 2008;53(7):465-75.
  46. Li J, Shi Y, Wan X, Qian H, Zhou C, Chen X. Epithelioid trophoblastic tumor: a clinicopathological and immunohistochemical study of seven cases. Medical oncology. 2011;28(1):294-9.
  47. Masselli G, Gualdi G. MR imaging of the placenta: what a radiologist should know. Abdominal imaging. 2013;38(3):573-87.
  48. Dhillon T, Palmieri C, Sebire NJ, Lindsay I, Newlands ES, Schmid P, et al. Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med. 2006;51(11):879-87.
  49. Nieves L, Hoffman J, Allen G, Currie J, Sorosky JI. Placental-site trophoblastic tumor with PET scan-detected surgically treated lung metastasis. International journal of clinical oncology. 2008;13(3):263-5.
  50. Chang TC, Yen TC, Li YT, Wu YC, Chang YC, Ng KK, et al. The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours: a pilot study. European journal of nuclear medicine and molecular imaging. 2006;33(2):156-63.
  51. Elsayes KM, Trout AT, Friedkin AM, Liu PS, Bude RO, Platt JF, et al. Imaging of the placenta: a multimodality pictorial review. Radiographics : a review publication of the Radiological Society of North America, Inc. 2009;29(5):1371-91.
  52. Baird AM, Beckly DE, Ross FG. The ultrasound diagnosis of hydatidiform mole. Clinical radiology. 1977;28(6):637-45.
  53. Jauniaux E, Nicolaides KH. Early ultrasound diagnosis and follow-up of molar pregnancies. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 1997;9(1):17-21.
  54. Johns J, Greenwold N, Buckley S, Jauniaux E. A prospective study of ultrasound screening for molar pregnancies in missed miscarriages. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2005;25(5):493-7.
  55. Kirk E, Papageorghiou AT, Condous G, Bottomley C, Bourne T. The accuracy of first trimester ultrasound in the diagnosis of hydatidiform mole. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2007;29(1):70-5.
  56. Lindholm H, Flam F. The diagnosis of molar pregnancy by sonography and gross morphology. Acta obstetricia et gynecologica Scandinavica. 1999;78(1):6-9.
  57. Sebire NJ, Rees H, Paradinas F, Seckl M, Newlands E. The diagnostic implications of routine ultrasound examination in histologically confirmed early molar pregnancies. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2001;18(6):662-5.
  58. Zhou Q, Lei XY, Xie Q, Cardoza JD. Sonographic and Doppler imaging in the diagnosis and treatment of gestational trophoblastic disease: a 12-year experience. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2005;24(1):15-24.
  59. Timmerman D, Wauters J, Van Calenbergh S, Van Schoubroeck D, Maleux G, Van Den Bosch T, et al. Color Doppler imaging is a valuable tool for the diagnosis and management of uterine vascular malformations. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2003;21(6):570-7.
  60. Araujo Junior E, Sun SY, Campanharo FF, Nacaratto DC, Nardozza LM, Mattar R, et al. Diagnosis of ovarian metastasis from gestational trophoblastic neoplasia by 3D power Doppler ultrasound and dynamic contrast-enhanced magnetic resonance imaging: case report. Case Rep Oncol.5(2):359-66.
  61. Zhou Y, Lu H, Yu C, Tian Q, Lu W. Sonographic characteristics of placental site trophoblastic tumor. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
  62. Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24 Suppl 6:vi39-50.
  63. Flam F, Lundstrom V, Silfversward C. Choriocarcinoma in mother and child. Case report. British journal of obstetrics and gynaecology. 1989;96(2):241-4.
  64. Oncology FCoG. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2009;105(1):3-4.
  65. Ronnett BM, DeScipio C, Murphy KM. Hydatidiform moles: ancillary techniques to refine diagnosis. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2011;30(2):101-16.
  66. Vang R, Gupta M, Wu LS, Yemelyanova AV, Kurman RJ, Murphy KM, et al. Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis. The American journal of surgical pathology. 2012;36(3):443-53.
  67. Fukunaga M, Katabuchi H, Nagasaka T, Mikami Y, Minamiguchi S, Lage JM. Interobserver and intraobserver variability in the diagnosis of hydatidiform mole. The American journal of surgical pathology. 2005;29(7):942-7.
  68. Niemann I, Hansen ES, Sunde L. The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy. Gynecologic oncology. 2007;104(2):411-5.
  69. Castrillon DH, Sun D, Weremowicz S, Fisher RA, Crum CP, Genest DR. Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2. The American journal of surgical pathology. 2001;25(10):1225-30.
  70. Fukunaga M. Immunohistochemical characterization of p57(KIP2) expression in early hydatidiform moles. Human pathology. 2002;33(12):1188-92.
  71. Jeffers MD, Richmond JA, Smith R. Trophoblast proliferation rate does not predict progression to persistent gestational trophoblastic disease in complete hydatidiform mole. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 1996;15(1):34-8.
  72. WHO classification of tumour of female reproductive organs. 4th ed. Lyon: IARC; 2014.
  73. Szulman AE, Surti U. The syndromes of hydatidiform mole. II. Morphologic evolution of the complete and partial mole. American journal of obstetrics and gynecology. 1978;132(1):20-7.
  74. Murphy KM, McConnell TG, Hafez MJ, Vang R, Ronnett BM. Molecular genotyping of hydatidiform moles: analytic validation of a multiplex short tandem repeat assay. The Journal of molecular diagnostics : JMD. 2009;11(6):598-605.
  75. Howat AJ, Beck S, Fox H, Harris SC, Hill AS, Nicholson CM, et al. Can histopathologists reliably diagnose molar pregnancy? Journal of clinical pathology. 1993;46(7):599-602.
  76. Lurain JR, Brewer JI. Invasive mole. Seminars in oncology. 1982;9(2):174-80.
  77. Hui P. Gestational Trophoblastic Disease: Diagnostic and Molecular Genetic Pathology. Giordano A, editor: Humana press, New York; 2012.
  78. Kurman RJe. Blaustein’s Pathology of the Female Genital Tract: Springer Verlag; 2011.
  79. Oladipo A, Mathew J, Oriolowo A, Lindsay I, Fisher R, Seckl M, et al. Nongestational choriocarcinoma arising from a primary ovarian tumour. BJOG : an international journal of obstetrics and gynaecology. 2007;114(10):1298-300.
  80. Park SH, Park A, Kim JY, Kwon JH, Koh SB. A case of non-gestational choriocarcinoma arising in the ovary of a postmenopausal woman. Journal of gynecologic oncology. 2009;20(3):192-4.
  81. Mao TL, Kurman RJ, Huang CC, Lin MC, Shih Ie M. Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. The American journal of surgical pathology. 2007;31(11):1726-32.
  82. Niehans GA, Manivel JC, Copland GT, Scheithauer BW, Wick MR. Immunohistochemistry of germ cell and trophoblastic neoplasms. Cancer. 1988;62(6):1113-23.
  83. Shih IM, Kurman RJ. Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: a double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. Human pathology. 1998;29(1):27-33.
  84. Allison KH, Love JE, Garcia RL. Epithelioid trophoblastic tumor: review of a rare neoplasm of the chorionic-type intermediate trophoblast. Archives of pathology & laboratory medicine. 2006;130(12):1875-7.
  85. Young RH, Kurman RJ, Scully RE. Placental site nodules and plaques. A clinicopathologic analysis of 20 cases. The American journal of surgical pathology. 1990;14(11):1001-9.
  86. Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2001;20(1):31-47.
  87. Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, Francis RJ, Short D, et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet. 2002;359(9324):2165-6.
  88. Steller MA, Genest DR, Bernstein MR, Lage JM, Goldstein DP, Berkowitz RS. Clinical features of multiple conception with partial or complete molar pregnancy and coexisting fetuses. J Reprod Med. 1994;39(3):147-54.
  89. Matsui H, Sekiya S, Hando T, Wake N, Tomoda Y. Hydatidiform mole coexistent with a twin live fetus: a national collaborative study in Japan. Human reproduction. 2000;15(3):608-11.
  90. Seckl MJ, Dhillon T, Dancey G, Foskett M, Paradinas FJ, Rees HC, et al. Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy? J Reprod Med. 2004;49(7):527-30.
  91. Niemann I, Fisher, R., Sebire, N., Wells, M., Short, D., Tidy, J., Hancock, B., Coleman, R., Savage, P.,Seckl, M. Update on UK outcomes for women with twin pregnancies comprising a complete hydatidiform mole (CHM) and normal co-twin. ISSTD World Congress XVII, Chicago. 2013.
  92. Massardier J, Golfier F, Journet D, Frappart L, Zalaquett M, Schott AM, et al. Twin pregnancy with complete hydatidiform mole and coexistent fetus: obstetrical and oncological outcomes in a series of 14 cases. European journal of obstetrics, gynecology, and reproductive biology. 2009;143(2):84-7.
  93. Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecologic oncology. 2000;78(3 Pt 1):309-12.
  94. Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2013;33(4):406-11.
  95. Hassadia A, Gillespie A, Tidy J, Everard RGNJ, Wells M, Coleman R, et al. Placental site trophoblastic tumour: clinical features and management. Gynecologic oncology. 2005;99(3):603-7.
  96. Machtinger R, Gotlieb WH, Korach J, Fridman E, Apter S, Goldenberg M, et al. Placental site trophoblastic tumor: outcome of five cases including fertility preserving management. Gynecologic oncology. 2005;96(1):56-61.
  97. Saso S, Haddad J, Ellis P, Lindsay I, Sebire NJ, McIndoe A, et al. Placental site trophoblastic tumours and the concept of fertility preservation. BJOG : an international journal of obstetrics and gynaecology. 2012;119(3):369-74; discussion 74.
  98. McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). British journal of cancer. 2010;102(5):810-4.
  99. Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecologic oncology. 2012;125(3):576-9.
  100. Hancock B. The UK experience with MTX-FA for treatment of low-risk GTN. ISSTD Word Congress XVII, Chicago. 2012.
  101. Savage P. Follow up and long term health issues after treatment for GTN. ISSTD World Congress, Chicago. 2013.
  102. Hartenbach EM, Saltzman AK, Carter JR, Twiggs LB. A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease. Gynecologic oncology. 1995;56(1):105-8.
  103. Blohm ME, Gobel U. Unexplained anaemia and failure to thrive as initial symptoms of infantile choriocarcinoma: a review. European journal of pediatrics. 2004;163(1):1-6.
  104. Sebire NJ, Lindsay I, Fisher RA, Seckl MJ. Intraplacental choriocarcinoma: experience from a tertiary referral center and relationship with infantile choriocarcinoma. Fetal and pediatric pathology. 2005;24(1):21-9.
  105. Newlands ES, Holden L, Seckl MJ, McNeish I, Strickland S, Rustin GJ. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med. 2002;47(6):465-71.
  106. Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(7):2636-43.
  107. Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, et al. The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. British journal of cancer. 2006;95(9):1145-7.
  108. Bakri YN, Berkowitz RS, Khan J, Goldstein DP, von Sinner W, Jabbar FA. Pulmonary metastases of gestational trophoblastic tumor. Risk factors for early respiratory failure. J Reprod Med. 1994;39(3):175-8.
  109. Coyle C, Short, D., Dayal, L., Horsley, L., Sebire, N., Kaur, B.,, Harvey, R., Savage, P., Seckl, M. Frequency of persistent gestational trophoblastic disease (PTD) after spontaneous normalisation of hCG following a hydatidiform molar (HM) pregnancy. ISSTD World Congress XVII, Chicado. 2013.
  110. Rodriguez GC, Hughes CL, Soper JT, Berchuck A, Clarke-Pearson DL, Hammond CB. Serum progesterone for the exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia. Obstetrics and gynecology. 1994;84(5):794-7.
  111. Berkowitz RS, Goldstein DP, Marean AR, Bernstein M. Oral contraceptives and postmolar trophoblastic disease. Obstetrics and gynecology. 1981;58(4):474-7.
  112. Braga A, Short, D., Maesta, I., Savage, P., Harvey, R., Seckl, M. Modern hormonal contraception use before hCG remission does not increase the risk of persistent trophoblastic disease following complete hydatiform mole. 2913.
  113. Gaffield ME, Kapp N, Curtis KM. Combined oral contraceptive and intrauterine device use among women with gestational trophoblastic disease. Contraception. 2009;80(4):363-71.
  114. Garrett LA, Garner EI, Feltmate CM, Goldstein DP, Berkowitz RS. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med. 2008;53(7):481-6.
  115. Matsui H, Iitsuka Y, Suzuka K, Yamazawa K, Seki K, Sekiya S. Outcome of subsequent pregnancy after treatment for persistent gestational trophoblastic tumour. Human reproduction. 2002;17(2):469-72.
  116. Sebire NJ, Fisher RA, Foskett M, Rees H, Seckl MJ, Newlands ES. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG : an international journal of obstetrics and gynaecology. 2003;110(1):22-6.
  117. Joneborg U, Eloranta S, Johansson AL, Marions L, Weibull CE, Lambe M. Hydatidiform mole and subsequent pregnancy outcome: a population-based cohort study. American journal of obstetrics and gynecology. 2014;211(6):681 e1-7.
  118. by  Cortés-Charry R, Corredor, N., García,  N., Fernández, J., Salazar, A. , Fargioni, M. Human chorionic gonadotropin regression in non molar pregnancy: A preliminary study. ISSTD Word Congress XVII, Chicago. 2013.
  119. Fisher R. Risk of recurrent hydatiform mole after complete or partial molar pregnancy. ISSTD Word Congress XVII, Chicago. 2013.
  120. Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000;18(4):854-9.
  121. Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008;19(9):1578-83.
  122. Giacalone PL, Benos P, Donnadio D, Laffargue F. High-dose chemotherapy with autologous bone marrow transplantation for refractory metastatic gestational trophoblastic disease. Gynecologic oncology. 1995;58(3):383-5.
  123. Berkowitz RS, Bernstein MR, Laborde O, Goldstein DP. Subsequent pregnancy experience in patients with gestational trophoblastic disease. New England Trophoblastic Disease Center, 1965-1992. J Reprod Med. 1994;39(3):228-32.
  124. Rustin GJ, Booth M, Dent J, Salt S, Rustin F, Bagshawe KD. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. British medical journal. 1984;288(6411):103-6.
  125. Song HZ, Wu PC, Wang YE, Yang XY, Dong SY. Pregnancy outcomes after successful chemotherapy for choriocarcinoma and invasive mole: long-term follow-up. American journal of obstetrics and gynecology. 1988;158(3 Pt 1):538-45.
  126. Ayhan A, Ergeneli MH, Yuce K, Yapar EG, Kisnisci AH. Pregnancy after chemotherapy for gestational trophoblastic disease. J Reprod Med. 1990;35(5):522-4.
  127. Woolas RP, Bower M, Newlands ES, Seckl M, Short D, Holden L. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. British journal of obstetrics and gynaecology. 1998;105(9):1032-5.
  128. Wenzel L, Berkowitz R, Robinson S, Bernstein M, Goldstein D. The psychological, social, and sexual consequences of gestational trophoblastic disease. Gynecologic oncology. 1992;46(1):74-81.
  129. Wenzel LB, Berkowitz RS, Robinson S, Goldstein DP, Bernstein MR. Psychological, social and sexual effects of gestational trophoblastic disease on patients and their partners. J Reprod Med. 1994;39(3):163-7.
  130. Garner E, Goldstein DP, Berkowitz RS, Wenzel L. Psychosocial and reproductive outcomes of gestational trophoblastic diseases. Best practice & research Clinical obstetrics & gynaecology. 2003;17(6):959-68.
  131. Flam F, Magnusson C, Lundstrom-Lindstedt V, von Schoultz B. Psychosocial impact of persistent trophoblastic disease. Journal of psychosomatic obstetrics and gynaecology. 1993;14(4):241-8.
  132. Lok CA, Donker M, Calff MM, Massuger LF, Ansink AC. Psychologic impact of follow-up after low-risk gestational trophoblastic disease. J Reprod Med. 2011;56(1-2):47-52.
  133. Stafford L, McNally OM, Gibson P, Judd F. Long-term psychological morbidity, sexual functioning, and relationship outcomes in women with gestational trophoblastic disease. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(7):1256-63.
  134. McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(7):1838-44.
Nästa kapitel
26 Arbetsgruppen
Läs kapitel 26